

3.0 Guideline development: before consultation (to be completed by the developer before draft guideline consultation)

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equalities issues that would need to be addressed were identified.

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

No new equality issues have been identified.

3.3 Were the Committee's considerations of equality issues described in the consultation document, and, if so, where?

Consideration of equality issues would have been documented in the Linking Evidence to Recommendations table that accompanies the recommendations for each clinical question. However, the GC did not identify any potential issues.

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

We do not believe that the recommendations in this guideline should cause any difficulties with accessing services on the grounds of equality.

Completed by Developer

National Collaborating Centre for
Cancer

Date

30.07.2015

Approved by NICE quality assurance lead

Sarah Willett

Date

20.08.2015